These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 37368098)

  • 1. NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma.
    Maithel SK; Keilson JM; Cao HST; Rupji M; Mahipal A; Lin BS; Javle MM; Cleary SP; Akce M; Switchenko JM; Rocha FG
    Ann Surg Oncol; 2023 Oct; 30(11):6558-6566. PubMed ID: 37368098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical feasibility of curative surgery after nab-paclitaxel plus gemcitabine-cisplatin chemotherapy in patients with locally advanced cholangiocarcinoma.
    Choi SH; Kang I; Lee SH; Kang B; Cheon J; Kim DJ; Kim G; Kwon CI; Ko KH; Chon HJ
    Surgery; 2023 Feb; 173(2):280-288. PubMed ID: 36435652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
    Sahai V; Catalano PJ; Zalupski MM; Lubner SJ; Menge MR; Nimeiri HS; Munshi HG; Benson AB; O'Dwyer PJ
    JAMA Oncol; 2018 Dec; 4(12):1707-1712. PubMed ID: 30178032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial.
    Shroff RT; Javle MM; Xiao L; Kaseb AO; Varadhachary GR; Wolff RA; Raghav KPS; Iwasaki M; Masci P; Ramanathan RK; Ahn DH; Bekaii-Saab TS; Borad MJ
    JAMA Oncol; 2019 Jun; 5(6):824-830. PubMed ID: 30998813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II Study of Nab-Paclitaxel and Gemcitabine as First-Line Therapy in Patients with Cholangiocarcinoma Ineligible for Cisplatin-Based Chemotherapy (NACHO).
    Virchow I; Treckmann JW; Prasnikar N; Linden G; Markus P; Schumacher B; Albers D; Herold T; Ting S; Schmidt H; Radunz S; Wiesweg M; Siveke J; Schuler M; Kasper S
    Oncol Res Treat; 2023; 46(3):89-99. PubMed ID: 36623497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group.
    Seufferlein T; Uhl W; Kornmann M; Algül H; Friess H; König A; Ghadimi M; Gallmeier E; Bartsch DK; Lutz MP; Metzger R; Wille K; Gerdes B; Schimanski CC; Graupe F; Kunzmann V; Klein I; Geissler M; Staib L; Waldschmidt D; Bruns C; Wittel U; Fichtner-Feigl S; Daum S; Hinke A; Blome L; Tannapfel A; Kleger A; Berger AW; Kestler AMR; Schuhbaur JS; Perkhofer L; Tempero M; Reinacher-Schick AC; Ettrich TJ
    Ann Oncol; 2023 Jan; 34(1):91-100. PubMed ID: 36209981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ASO Author Reflections: NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma.
    Maithel SK
    Ann Surg Oncol; 2023 Oct; 30(11):6567-6568. PubMed ID: 37386309
    [No Abstract]   [Full Text] [Related]  

  • 9. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
    Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.
    Reni M; Zanon S; Balzano G; Passoni P; Pircher C; Chiaravalli M; Fugazza C; Ceraulo D; Nicoletti R; Arcidiacono PG; Macchini M; Peretti U; Castoldi R; Doglioni C; Falconi M; Partelli S; Gianni L
    Eur J Cancer; 2018 Oct; 102():95-102. PubMed ID: 30149366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic ductal adenocarcinoma.
    Chen EY; Kardosh A; Nabavizadeh N; Foster B; Mayo SC; Billingsley KG; Gilbert EW; Lanciault C; Grossberg A; Bensch KG; Maynard E; Anderson EC; Sheppard BC; Thomas CR; Lopez CD; Vaccaro GM;
    Cancer Med; 2023 Jun; 12(12):12986-12995. PubMed ID: 37132281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine and Cisplatin as Neo-Adjuvant for Cholangiocarcinoma Patients Prior to Liver Transplantation: Case-Series.
    Abdelrahim M; Al-Rawi H; Esmail A; Xu J; Umoru G; Ibnshamsah F; Abudayyeh A; Victor D; Saharia A; McMillan R; Al Najjar E; Bugazia D; Al-Rawi M; Ghobrial RM
    Curr Oncol; 2022 May; 29(5):3585-3594. PubMed ID: 35621680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma.
    Luvira V; Satitkarnmanee E; Pugkhem A; Kietpeerakool C; Lumbiganon P; Pattanittum P
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD012814. PubMed ID: 34515993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial.
    Jeong H; Kim KP; Jeong JH; Hwang DW; Lee JH; Kim KH; Moon DB; Lee MA; Park SJ; Chon HJ; Park JH; Lee JS; Ryoo BY; Yoo C
    Hepatology; 2023 May; 77(5):1540-1549. PubMed ID: 37070950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility and efficacy of gemcitabine plus cisplatin combination therapy after curative resection for biliary tract cancer.
    Kainuma O; Miura F; Furukawa D; Yamamoto H; Cho A; Sano K; Nakagohri T; Asano T
    J Hepatobiliary Pancreat Sci; 2015 Nov; 22(11):789-94. PubMed ID: 26234468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact.
    Kondo N; Uemura K; Sudo T; Hashimoto Y; Sumiyoshi T; Okada K; Seo S; Otsuka H; Murakami Y; Takahashi S
    Eur J Cancer; 2021 Dec; 159():215-223. PubMed ID: 34781169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study.
    Niger M; Nichetti F; Fornaro L; Pircher C; Morano F; Palermo F; Rimassa L; Pressiani T; Berardi R; Gardini AC; Sperti E; Salvatore L; Melisi D; Bergamo F; Siena S; Mosconi S; Longarini R; Arcangeli G; Corallo S; Delliponti L; Tamberi S; Fea E; Brandi G; Rapposelli IG; Salati M; Baili P; Miceli R; Ljevar S; Cavallo I; Sottotetti E; Martinetti A; Busset MDD; Sposito C; Di Bartolomeo M; Pietrantonio F; de Braud F; Mazzaferro V
    BMC Cancer; 2024 Apr; 24(1):436. PubMed ID: 38589856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study.
    Siebenhüner AR; Seifert H; Bachmann H; Seifert B; Winder T; Feilchenfeldt J; Breitenstein S; Clavien PA; Stupp R; Knuth A; Pestalozzi B; Samaras P
    BMC Cancer; 2018 Jan; 18(1):72. PubMed ID: 29325521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The AGITG GAP Study: A Phase II Study of Perioperative Gemcitabine and Nab-Paclitaxel for Resectable Pancreas Cancer.
    Barbour AP; Samra JS; Haghighi KS; Donoghoe MW; Burge M; Harris MT; Chua YJ; Mitchell J; O'Rourke N; Chan H; Gebski VJ; Gananadha S; Croagh DG; Kench JG; Goldstein D;
    Ann Surg Oncol; 2020 Jul; 27(7):2506-2515. PubMed ID: 31997125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sintilimab plus nab-paclitaxel as second-line treatment for advanced biliary tract cancer: study protocol for an investigator-initiated phase 2 trial (NapaSinti trial).
    Zhou N; Li X; Yang Y; Tan S; Zhang S; Huang Q; Gou H
    BMC Cancer; 2023 Aug; 23(1):729. PubMed ID: 37550655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.